What this trial means for you
This study is active, not recruiting. It is not currently taking new participants, but its results may matter for treatments you're considering. It's studying AZD6234, Placebo to match for endocrinology, diabetes, type ii, obesity.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: 1. Be 18 to 75 years old at the time of signing the informed consent. 2. Diagnosed with type 2 diabetes ≥ 180 days before screening. 3. HbA1c value at screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol). 4. On a stable maintenance dose of an injectable GLP-1 RA. 5. At Screening, have a BMI ≥ 27 kg/m2 Exclusion Criteria: 1. Has received treatment with prescription or non-prescription medication for weight loss within the last 3 months prior to screening (other than a GLP-1 RA). 2. Self-reported weight change of \> 5 % in the 3 months prior to screening. 3. Diabetes mellitus that is not clearly type 2 diabetes. 4. Use of insulin therapy for T2DM 5. Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier) 6. Significant hepatobiliary disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) 8\. Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73m2 at screening
Study sites by state
Alabama
- Research Site, Birmingham
- Research Site, Mobile
Florida
- Research Site, Doral
- Research Site, Jacksonville
- Research Site, Miami
- Research Site, Miami
- Research Site, Winter Park
Georgia
- Research Site, Canton
- Research Site, Fayetteville
Illinois
- Research Site, Chicago
- Research Site, Oak Brook
Kansas
- Research Site, Newton
Kentucky
- Research Site, Lexington
Missouri
- Research Site, Kansas City
Nevada
- Research Site, Las Vegas
Oklahoma
- Research Site, Norman
Tennessee
- Research Site, Knoxville
Texas
- Research Site, San Antonio
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.